Autologous T-Cells Encoding A Chimeric Antigen Receptor Targeting Human B Cell Maturation Antigen

2 trials 1 recruiting

Filter these 2 trials by condition, phase, country and more.

Open in Search →

2 Registered trials

1 Recruiting

1 Completed trials

2 Sponsors

12 Countries

Phase III

Phase II

Phase III: 1 Phase II: 1

Oversight events:

5 temporary halts across 1 trial

View oversight register →

Indications tested

B-cell lymphoma 1 B-cell type acute leukaemia 1

Sponsors using this IMP

Novartis Pharma AG 1 Novartis Pharma Services AG 1

All trials

2 total

CAR T-cell therapy long term follow-up Recruiting

2023-508128-37-00 Phase III 12 countries Novartis Pharma Services AG
A Phase 2 study of durcabtagene autoleucel, B-cell maturation Antigen (BCMA)-directed CAR-T Cells in adult participants with relapsed and re… Ended

2023-507140-37-00 Phase II 5 countries Novartis Pharma AG

Showing 1–2 of 2 trials

← All drugs A–Z